Workflow
国科恒泰: 长城证券股份有限公司关于国科恒泰(北京)医疗科技股份有限公司使用部分闲置募集资金暂时补充流动资金的核查意见

Core Viewpoint - The company intends to temporarily use part of its idle raised funds to supplement working capital, ensuring that this does not affect the normal progress of its fundraising investment projects [6][9]. Group 1: Fundraising Overview - The company was approved to publicly issue 70.6 million shares at a price of RMB 13.39 per share, raising a total of RMB 945.334 million, with a net amount of RMB 843.209 million after deducting issuance costs [2][3]. - As of the date of the verification opinion, the remaining balance of the raised funds is RMB 192.519 million, including oversubscription funds [6]. Group 2: Fund Utilization - The company has used RMB 496.663 million of the raised funds for third-party medical device logistics construction projects [4]. - The company plans to use up to RMB 92.75 million of idle raised funds temporarily to supplement working capital, with a usage period not exceeding 12 months [7][9]. Group 3: Approval and Oversight - The board of directors and the supervisory board have approved the use of idle funds, ensuring compliance with relevant regulations [9][10]. - The company will open a special account at a bank for the management of these funds and sign a tripartite supervision agreement to oversee the storage and usage of the raised funds [8]. Group 4: Financial Efficiency - By utilizing the idle funds, the company expects to save approximately RMB 2.78 million in financial costs based on the current loan market rate of 3.00% [8].